Cármino Antônio De Souza

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio et al. · The Lancet Oncology · 2011 · 513 citations

Life Sciences, Hematology, Pharmacotherapy +7

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

François Guilhot, Jane F. Apperley, Dong‐Wook Kim et al. · Blood · 2007 · 372 citations · Full text

Medicine, Hematology, Oncology +14

Outcome predictors of 84 patients with hematologic malignancies and <i>Fusarium</i> infection

Márcio Nucci, Elias Anaissie, Flávio Queiroz‐Telles et al. · Cancer · 2003 · 309 citations · Full text

Medicine, Hematology, Oncology +12

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Jörge E. Cortes, Michele Baccarani, François Guilhot et al. · Journal of Clinical Oncology · 2009 · 285 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10